Company Presentation Dec 09, 2024 Company Presentation Other Presentations November 3, 2023 SITC 2023: Epi-R P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time November 3, 2023 SITC 2023: Rejuvenation of tumor-infiltrating lymphocytes (TIL) through Partial Reprogramming November 3, 2023 SITC 2023: Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies November 3, 2023 SITC 2023: Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors June 14, 2023 Rejuvenation: Improving T-cell Antitumor Properties Through Partial Reprogramming May 17, 2023 Preclinical Development of LYL119, a ROR1-Targeted CAR T-Cell Product Candidate Incorporating Four Novel T-Cell Reprogramming Technologies to Overcome Barriers to Effective Cell Therapy for Solid Tumors November 11, 2022 The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity November 11, 2022 The Epi-R technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function November 11, 2022 Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform November 11, 2022 Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last »
